Clinical trial Recruiting at 5 sites Interventional Ages Any age to 21

Comparing Taurolidine and Saline Locks for Catheter Care in Children with Cancer

Official title: Multicentre Randomised Study Comparing a Taurolidine Lock and a Standard Saline Lock in the Primary Prevention of Catheter-related Endoluminal Infection in Paediatric Oncology.

Run by Institut Curie · NCT05781295 · Data updated 2026-11-12

This study tests whether using a Taurolidine lock instead of a regular saline lock can help prevent infections in central catheters for kids and young adults with cancer.

More Asthma in Children trials

Quick facts

Study typeInterventional
AgesAny age to 21 Years
SexAll
Enrollment148 (estimated)
SponsorInstitut Curie
Academic / other
Locations5 sites (Paris and 4 other locations)
StatusRecruiting
StartedJanuary 19, 2024
Main results expectedJuly 23, 2028
Study endsJuly 23, 2028
Registry record updatedFebruary 20, 2026
Trial IDNCT05781295 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are children and young adults up to 21 years old who are undergoing treatment for cancer and require a central catheter.

Probably not a fit

Patients with retinoblastoma, those who are allografted, or those with a life expectancy of less than 6 months may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This multicentric, controlled, randomized, and double-blind study aims to evaluate the effectiveness of a Taurolidine lock compared to a standard saline lock in preventing catheter-related endoluminal infections in pediatric oncology patients. Participants will be monitored based on their specific cancer treatment protocols, with either Taurolock or physiological serum used at each catheter closure. The study focuses on children and young adults up to 21 years of age who require central catheter placement for cancer treatment.

Why it matters

Potential benefit: If successful, this study could significantly reduce the incidence of infections related to central catheters in pediatric oncology patients.

How similar studies have gone: Previous studies have shown promising results with the use of Taurolidine in preventing infections in similar patient populations, indicating potential for success in this approach.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

1. Patient less than or equal to 21 years of age at inclusion.
2. Patient for whom a central catheter is planned to be inserted\*, excluding a non-tunneled femoral or cervical external catheter or a peripherally inserted central catheter (as PICC line). \*1st catheter placement or placement following a relapse (this placement must take place at least one month after previous catheter removal).
3. Patient treated for a cancer.
4. Patient with regular follow-up in the inclusion center.
5. Informed consent signed by the patient if adult or by legal representatives if minor.
6. Patient benefiting from a social security coverage.
7. Time between the date of catheter placement and the planned date for the first solution lock injection less than 6 weeks.

Exclusion Criteria:

1. Patient with retinoblastoma.
2. Allografted patient.
3. Patient with a life expectancy of less than 6 months.
4. Patient refusing to participate in the protocol.
5. Patient already receiving a central venous catheter-related infection prevention lock (ILCVC).
6. Patient with known allergy to citrate or (cyclo)-Taurolidine.
7. Patient taking other drugs with a known contraindication with citrate or (cyclo)-Taurolidine.
8. Patient with an external femoral catheter.
9. Patient with a PICCLINE-type peripheral venous inserted central catheter.
10. Patient unable to submit to the medical follow-up of the trial for geographical, social or psychological reasons.
11. Patient under guardianship and curatorship.

Where it's running

  • Institut Curie
    Paris, France
    Recruiting
  • Saint Louis
    Paris, France
    Recruiting
  • Armand Trousseau
    Paris, France
    Recruiting
  • Robert Debre
    Paris, France
    Recruiting
  • Gustave Roussy
    Villejuif, France
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.